March 5, 2024 07:15 AM EST
Deals
Manufacturing

Aus­tralian bio­phar­ma buys ra­dioiso­tope pro­duc­er in its next step to ‘dou­ble’ ca­pac­i­ty in 2024 

Anna Brown

News Reporter

Telix Phar­ma­ceu­ti­cals is still on its ra­dio­phar­ma man­u­fac­tur­ing shop­ping spree. The Aus­tralian biotech is buy­ing com­mer­cial-stage ra­dioiso­tope pro­duc­er ARTMS for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times